TBRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
TBRG is not a good buy right now for an impatient buyer. The stock is in a clear downtrend (bearish moving averages and worsening MACD), and the near-term pattern stats also lean slightly negative. While it’s getting oversold near support (~$19.22) and options positioning is mildly bullish, the tape hasn’t confirmed a reversal and recent profitability collapsed in the latest reported quarter. I’d wait rather than chase this dip.
Price/Trend: Bearish structure with SMA_200 > SMA_20 > SMA_5, indicating the stock is trending down across long-, mid-, and short-term timeframes. Momentum: MACD histogram is -0.18 and negatively expanding, suggesting downside momentum is still increasing (no reversal signal yet). RSI: RSI_6 at 22.16 is oversold (despite the provided label calling it neutral), which can support a short-term bounce, but oversold can persist in a downtrend. Levels: Current ~19.35 is sitting just above S1 at 19.223 (near-term support). A clean breakdown below 19.22 increases risk toward S2 at 18.579. Upside hurdles are the pivot at 20.266, then R1 at 21.309. For an impatient entry, the setup is unfavorable until price regains ~20.27 and momentum stabilizes.
Execution and traction in the Revenue Cycle Management (RCM) realignment could re-rate the stock if growth improves. (
Stable Electronic Health Records (EHR) base may provide revenue stability if RCM ramps. (
Oversold technical condition near support (~$19.
could produce a short-lived mean-reversion bounce if support holds.
Ongoing downtrend with worsening MACD suggests sellers still control the tape; a break below ~$19.22 opens room toward ~$18.
(
Recent periods of low growth and execution risk highlighted by RBC; the market may require proof of RCM traction before bidding shares higher. (
Latest quarter showed a major profitability deterioration (net income/EPS down sharply YoY), which can cap near-term upside until margins/earnings normalize. Newsflow: No recent news this week, so there’s no obvious event-driven catalyst to change the trend immediately.
Latest reported quarter: 2025/Q3. Revenue was $86.106M, up 1.66% YoY (low growth). Profitability deteriorated sharply: Net income $5.423M, down -161.79% YoY; EPS $0.37, down -160.66% YoY. Gross margin improved to 43.35% (+2.36% YoY), but the earnings decline overwhelms the margin improvement, indicating higher costs/other items or non-operating impacts pressured the bottom line. Overall: modest revenue growth with a significant earnings setback is not supportive for an immediate buy.
Recent analyst stance is cautious/neutral: (1) RBC (2026-01-09) resumed at Sector Perform with a $23 PT, citing RCM opportunity + stable EHR but highlighting execution risk after low-growth periods. (2) BMO (2025-11-12) initiated at Market Perform with a $19.50 PT, viewing the RCM shift as more attractive but wanting clearer traction before turning positive. Wall Street pros: credible strategic pivot (RCM) and stable core (EHR). Cons: execution risk and lack of demonstrated growth acceleration; ratings remain “perform/market perform” rather than “buy.” Influential trading: Hedge funds and insiders are neutral; no recent Congress trading data in the last 90 days.
